Human Tumor Xenograft Models in NCI Drug Development
Human Tumor Xenograft Models in NCI Drug Development
复制标题
DOI：
10.1007/978-1-4615-8152-9_6
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
J. Plowman;D. Dykes;M. Hollingshead;L. Simpson-Herren;M. Alley
中科院分区：
文献类型：
--
作者：
J. Plowman;D. Dykes;M. Hollingshead;L. Simpson-Herren;M. Alley
NCI抗癌药物的临床前发现和开发包括一系列测试程序、数据审查和决策步骤，这些步骤最近已被总结（1）。测试程序的目的是提供比较性的定量数据，从而可以从给定的化学或生物类别中选择最佳候选物剂。由各个NCI委员会定期进行的全面审查不仅用于鉴定和加速开发可为人类恶性肿瘤提供更有效治疗的活性先导化合物，而且还用于从进一步考虑中排除无活性和/或高毒性的药剂。
The preclinical discovery and development of anticancer drugs by the NCI consist of a series of test procedures, data review, and decision steps that have been summarized recently (1). Test procedures are designed to provide comparative quantitative data, which in turn, permit selection of the best candidate agents from a given chemical or biological class. Periodic, comprehensive reviews by various NCI committees serve not only to identify and expedite the development of active lead compounds that may provide more efficacious treatments for human malignancy, but also to eliminate agents that are inactive and/or highly toxic from further consideration.